CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Pfizer Bets on Weight Loss Drugs with Metsera Acquisition

After a period of challenges, including the recent termination of its danuglipron program, Pfizer (NYSE: PFE) has announced plans to acquire Metsera (MTSR), a pharmaceutical company specializing in obesity treatments. The announcement sent Pfizer's stock up by 2.1% as of 12:25 p.m. ET.

Acquisition Details

Pfizer will pay $47.50 per share upfront to acquire all of Metsera's stock, with potential milestone payments of $22.50 per share upon achievement of certain drug development milestones. The total deal value could reach $7.2 billion. Metsera focuses on developing incretin and amylin-based therapies, and its pipeline includes: * MET-097i: An injectable GLP-1 weight loss drug in Phase 2 clinical trials. * MET-233i: An injectable GLP-1 drug in Phase 1 clinical trials. * Two preclinical oral GLP-1 candidates.

Pfizer's Valuation and Risks

This acquisition represents a significant investment for Pfizer, which has a market capitalization of over $136 billion. While Pfizer's price-to-free-cash-flow (FCF) ratio is reasonable, its $50 billion in net debt (primarily from prior acquisitions) inflates its enterprise value-to-FCF ratio to 15. Given analyst expectations of shrinking profits for Pfizer in the coming years, this investment carries significant risk. The success of this acquisition hinges on Metsera's drugs gaining regulatory approval and achieving projected sales. If these drugs fail, Pfizer could end up paying twice the value of Metsera stock and significantly reduce the return on investment.

Risk Warning and Disclaimer: This article represents only the author’s views and is for reference only. It does not constitute investment advice or financial guidance, nor does it represent the stance of the Markets.com platform. Trading Contracts for Difference (CFDs) involves high leverage and significant risks. Before making any trading decisions, we recommend consulting a professional financial advisor to assess your financial situation and risk tolerance. Any trading decisions based on this article are at your own risk.

Senaste nyheterna

Lördag, 11 Oktober 2025

Indices

Stablecoins as Key U.S. Treasury Market Players: A Look at Shifting Dynamics

Lördag, 11 Oktober 2025

Indices

Powell Paves Way for Rate Cut, But Economic Data Could Upend Bets

Lördag, 11 Oktober 2025

Indices

Japan PM Ishiba's Approval Ratings Surge Amid Election Performance Review